Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02776059 · ClinicalTrials.gov registry record · Phase 2
Pegfilgrastim in Patients With Alcoholic Hepatitis
A Phase 2 study, sponsored by Timothy Morgan, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02776059 is a Phase 2 study that has completed, run by Timothy Morgan, MD. The registered enrollment target is 34 participants.
The verdict
NCT02776059, a Phase 2 study, has completed, sponsored by Timothy Morgan, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a multi-center, prospective, randomized trial of standard of care vs. standard of care + pegfilgrastim (Neulasta®) among patients with a clinical diagnosis of alcoholic hepatitis and DF≥32.
Interventions
- DRUG Standard of care
- DRUG Standard of care + pegfiltrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-01-21 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02776059
The ClinicalTrials.gov registry entry for NCT02776059 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Timothy Morgan, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of care is the first listed.
NCT02776059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02776059 about?
NCT02776059 is a clinical study titled "Pegfilgrastim in Patients With Alcoholic Hepatitis". This is a multi-center, prospective, randomized trial of standard of care vs. standard of care + pegfilgrastim (Neulasta®) among patients with a clinical diagnosis of alcoholic hepatitis and DF≥32.
What is the current status of trial NCT02776059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2017-01-21. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT02776059?
The interventions under investigation include: Standard of care (DRUG), Standard of care + pegfiltrastim (DRUG).
Who is sponsoring clinical trial NCT02776059?
This trial is sponsored by Timothy Morgan, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.